

MD7511 Injectable Therapies

Injectable Therapies

View Online



1

Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

2

Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.myilibrary.com?id=269077>

3

Crasto, W. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition 2016.
<https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975>

4

Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes
Systematic review and mixed-treatment comparison analysis.
<http://onlinelibrary.wiley.com.ezproxy3.lib.le.ac.uk/doi/10.1111/dom.12849/epdf>

5

Holt RIG, Cockram C, Flyvbjerg A, et al. Textbook of Diabetes. 5th ed. Somerset: : John Wiley & Sons, Incorporated 2016.
<http://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4769056>

6

Holt RIG. Textbook of diabetes. 4th ed. Chichester: : Wiley-Blackwell 2010.
<http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=269077>

7

Evans M, Schumm-Draeger PM, Vora J, et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism* 2011;**13**:677–84.
doi:10.1111/j.1463-1326.2011.01395.x

8

Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism* 2016;**18**:203–16. doi:10.1111/dom.12591

9

Ismail-Beigi F. Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine* 2012;**366**:1319–27. doi:10.1056/NEJMcp1013127

10

Nathan DM, Buse JB, Davidson MB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2006;**29**:1963–72.
doi:10.2337/dc06-9912

11

Srinivasan BT, Davies M. Glycaemic management of type 2 diabetes. *Medicine* 2014;**42**:711–7. doi:10.1016/j.mpmed.2014.09.011

12

Srinivasan BT, Jarvis J, Khunti K, et al. Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal* 2008;**84**:524–31.
doi:10.1136/pgmj.2008.067918

13

Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism* 2012;**14**:780–8. doi:10.1111/j.1463-1326.2012.01580.x

14

June James. Safety and insulin: implementation of national guidance at a local level. *Journal of Diabetes Nursing*
http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=8&docId=GALE%7CA342482979&docType=Article&sort=RELEVANCE&contentSegment=&prodId=EAIM&contentSet=GALE%7CA342482979&searchId=R6&userGroupName=leicester&inPS=true

15

Rorsman P, Renström E. Insulin granule dynamics in pancreatic beta cells. *Diabetologia* 2003;**46**:1029–45. doi:10.1007/s00125-003-1153-1

16

L. Luzi. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. *American Journal of Physiology - Endocrinology and Metabolism* 1989;**257**:E241–6. <http://ajpendo.physiology.org.ezproxy4.lib.le.ac.uk/content/257/2/E241>

17

Luc JC van Loon. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *The American Journal of Clinical Nutrition* 2000;**72**:96–105. <http://ajcn.nutrition.org/content/72/1/96.full>

18

Menting JG, Whittaker J, Margetts MB, et al. How insulin engages its primary binding site on the insulin receptor. *Nature* 2013;**493**:241–5. doi:10.1038/nature11781

19

Wahren J, Kallas A. Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? *Diabetes* 2012;**61**:2228–9. doi:10.2337/db12-0664

20

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes.
4AD.<https://www.youtube.com/watch?v=AhhWTmEFuag>

21

Hermansen K, Davies M, Derezinski T, et al. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care* 2006;**29**:1269–74. doi:10.2337/dc05-1365

22

Richter B, Neises G. 'Human' insulin versus animal insulin in people with diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD003816.pub2

23

Holman RR, Turner RC. A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine* 1985;**2**:45–53. doi:10.1111/j.1464-5491.1985.tb00592.x

24

Crasto, W. *Handbook of Insulin Therapies*. Adis; 1st ed. 2016 edition 2016.
<https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975>

25

Crasto W, Jarvis J, Hackett E, et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. *Postgraduate Medical Journal* 2009;**85**:219–22.
doi:10.1136/pgmj.2008.073379

26

Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD006383.pub2

27

Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet* 2008;**371**:1073–84. doi:10.1016/S0140-6736(08)60485-7

28

Davies MJ, Donnelly R, Barnett AH, et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism* 2009;**11**:1153–62. doi:10.1111/j.1463-1326.2009.01154.x

29

Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism* 2007;**9**:630–9. doi:10.1111/j.1463-1326.2006.00654.x

30

Holman RR, Thorne KI, Farmer AJ, et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine* 2007;**357**:1716–30. doi:10.1056/NEJMoa075392

31

Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD005613.pub3

32

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. <http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-005-0132-0/fulltext.html>

33

Riddle MC, Aronson R, Home P, et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care* 2013;**36**:2489–96. doi:10.2337/dc12-2454

34

Gough SCL, Bhargava A, Jain R, et al. Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. *Diabetes Care* 2013;**36**:2536–42. doi:10.2337/dc12-2329

35

Hirsch IB, Buse JB, Leahy J, et al. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism* 2014;**16**:206–14. doi:10.1111/dom.12136

36

Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet* 2011;**377**:924–31. doi:10.1016/S0140-6736(10)62305-7

37

Young LA, Buse JB. GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet* 2014;**384**:2180–1. doi:10.1016/S0140-6736(14)61409-4

38

Rosenstock J, Raccach D, Koranyi L, et al. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care* 2013;**36**:2945–51. doi:10.2337/dc12-2709

39

Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet* 2010;**375**:2234–43. doi:10.1016/S0140-6736(10)60406-0

40

New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes.

<http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/>

41

Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD005613.pub3

42

Buse JB, Bergenstal RM, Glass LC, et al. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine* 2011;**154**. doi:10.7326/0003-4819-154-2-201101180-00300

43

Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. *Diabetes Care* 2014;**37**:1815–23. doi:10.2337/dc13-3055

44

Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine* 2014;**31**:1293–300. doi:10.1111/dme.12561

45

Hirsch IB, Franek E, Mersebach H, et al. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). *Diabetic Medicine* 2017;**34**:167–73. doi:10.1111/dme.13068

46

Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. *Diabetic Medicine* 2017;**34**:189–96. doi:10.1111/dme.13256

47

Davies MJ, Leiter LA, Guerci B, et al. Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. *Diabetes, Obesity and Metabolism* Published Online First: April 2017. doi:10.1111/dom.12980

48

Raccah D, Huet D, Dib A, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine* Published Online First: 2 June 2017. doi:10.1111/dme.13390

49

Daly H, Davies M, Barnett J, et al. Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes* 2015;**32**:305–310a. doi:10.1002/pdi.1979

50

Crasto, W. Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition 2016.
<https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975>

51

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.

<http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-007-0911-x/fulltext.html>

52

Hannele Yki-Jarvinen, Leena Juurinen, Michael Alvarsson, Tord Bystedt, Ian Caldwell, Melanie Davies. Initiate insulin by aggressive titration and education (Initiate): randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care

http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Clinical+report&tabID=T002&prodId=EAIM&searchId=R1&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=¤tPosition=5&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA165017903&contentSet=GALE%7CA165017903

53

Philip Raskin, Elsie Allen, Priscilla Hollander, Andrew Lewin, Robert A. Gabbay, Peter Hu. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care

http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Article&tabID=T002&prodId=EAIM&searchId=R5&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=¤tPosition=5&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA128867472&contentSet=GALE%7CA128867472

54

Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine 2008; **359**:1577–89.
doi:10.1056/NEJMoa0806470

55

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. *New England Journal of Medicine* 2012;**367**:319–28. doi:10.1056/NEJMoa1203858

56

Goudswaard AN, Furlong NJ, Valk GD, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD003418.pub2

57

Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. *The Lancet Diabetes & Endocrinology* 2013;**1**:28–34. doi:10.1016/S2213-8587(13)70006-8

58

Holman RR, Farmer AJ, Davies MJ, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. *New England Journal of Medicine* 2009;**361**:1736–47. doi:10.1056/NEJMoa0905479

59

Yki-Jarvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. *Diabetes Care* 2007;**30**:1364–9. doi:10.2337/dc06-1357

60

Davies M, Storms F, Shutler S, et al. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care* 2005;**28**:1282–8. doi:10.2337/diacare.28.6.1282

61

Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal

insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. *The Lancet* 2014;**384**:2228–34. doi:10.1016/S0140-6736(14)61335-0

62

Yki-Jarvinen H, Kotronen A. Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? *Diabetes Care* 2013;**36**:S205–11. doi:10.2337/dcS13-2026

63

Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. *Diabetologia* 2009;**52**:1990–2000. doi:10.1007/s00125-009-1468-7

64

Wang C, Mamza J, Idris I. Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Diabetic Medicine* 2015;**32**:585–94. doi:10.1111/dme.12694

65

Davies MJ, Chatterjee S. Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. *Nature Reviews Endocrinology* 2017;**13**:317–8. doi:10.1038/nrendo.2017.41

66

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.
<http://www.journalslibrary.nihr.ac.uk/hta/volume-14/issue-11>

67

Crasto, W. *Handbook of Insulin Therapies*. Adis; 1st ed. 2016 edition 2016.
<https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975>

68

Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *The Lancet* 2012;**379**:1489–97. doi:10.1016/S0140-6736(12)60204-9

69

Davies MJ, Gross JL, Ono Y, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. *Diabetes, Obesity and Metabolism* 2014;**16**:922–30. doi:10.1111/dom.12298

70

Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine* 2006;**23**:285–92. doi:10.1111/j.1464-5491.2005.01781.x

71

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *New England Journal of Medicine* 1993;**329**:977–86. doi:10.1056/NEJM199309303291401

72

Nathan DM. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. *Diabetes Care* 2014;**37**:9–16. doi:10.2337/dc13-2112

73

Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine* 2010;**363**:311–20. doi:10.1056/NEJMoa1002853

74

Kahler P, Grevstad B, Almdal T, et al. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. *BMJ Open* 2014;**4**:e004806–e004806. doi:10.1136/bmjopen-2014-004806

75

Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. Chichester, UK: : John Wiley & Sons, Ltd 1996. doi:10.1002/14651858.CD009122.pub2

76

Benkhadra K, Alahdab F, Tamhane S, et al. Real Time Continuous Glucose Monitoring in type 1 diabetes: A Systematic review and Individual Patient Data Meta-Analysis. *Clinical Endocrinology* Published Online First: December 2016. doi:10.1111/cen.13290

77

McCrimmon RJ. Old habits are hard to break: lessons from the study of hypoglycaemia. *Diabetic Medicine* 2017;**34**:148–55. doi:10.1111/dme.13277

78

Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabetic Medicine* 2004;**21**:769–75. doi:10.1111/j.1464-5491.2004.01244.x

79

Pickup JC, Reznik Y, Sutton AJ. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. *Diabetes Care* 2017;**40**:715–22. doi:10.2337/dc16-2201

80

Wang W, Liu H, Xiao S, et al. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes Therapy* Published Online First: 14 June 2017.

doi:10.1007/s13300-017-0282-3

81

Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine* 2017;**34**:1205–11. doi:10.1111/dme.13379

82

Walker RA, Rodgers J, Diabetes UK. *Diabetes: a practical guide to managing your health*. Fully revised and updated. London: : Dorling Kindersley 2010.

83

Holman RR, Farmer AJ, Davies MJ, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. *New England Journal of Medicine* 2009;**361**:1736–47. doi:10.1056/NEJMoa0905479

84

Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? *Diabetes, Obesity and Metabolism* 2007;**9**:209–17. doi:10.1111/j.1463-1326.2006.00665.x

85

Anderson JW, Kendall CWC, Jenkins DJA. Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies. *Journal of the American College of Nutrition* 2003;**22**:331–9. doi:10.1080/07315724.2003.10719316

86

Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. *Diabetes, Obesity and Metabolism* 2007;**9**:799–812. doi:10.1111/j.1463-1326.2006.00686.x

87

Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. *BMJ* 2002;**325**:746–746. doi:10.1136/bmj.325.7367.746

88

Anderson B, Funnell M, American Diabetes Association. *The art of empowerment: stories and strategies for diabetes educators*. 2nd ed. Alexandria, Va: : American Diabetes Association 2005.

89

Insulin treatment and the problem of weight gain in type 2 diabetes. - PubMed - NCBI. <http://www.ncbi.nlm.nih.gov/pubmed/17102158>

90

Tikkanen-Dolenc H, Wadén J, Forsblom C, et al. Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes. *Diabetologia* Published Online First: 24 December 2016. doi:10.1007/s00125-016-4189-8

91

Peter Mansell. The dose adjustment for normal eating (DAFNE) education programme. *Journal of Diabetes Nursing*
http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=1&docId=GALE%7CA314268073&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA314268073&searchId=R1&userGroupName=leicester&inPS=true

92 :

Summary of Revisions. *Diabetes Care* 2016;**39**:S4–5. doi:10.2337/dc16-S003

93

Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New England Journal of Medicine* 2008;**358**:2545–59. doi:10.1056/NEJMoa0802743

94

Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism* 2006;**8**:58–66. doi:10.1111/j.1463-1326.2005.00563.x

95

Owens DR. Stepwise intensification of insulin therapy in Type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice. *Diabetic Medicine* 2013;**30**:276–88. doi:10.1111/dme.12019

96

Davies M, Storms F, Shutler S, et al. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care* 2005;**28**:1282–8. doi:10.2337/diacare.28.6.1282

97

Park SW, Bebakar WMW, Hernandez PG, et al. Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST : SIMPLE USE). *Diabetic Medicine* 2017;**34**:174–9. doi:10.1111/dme.13069

98

Matthew C. Riddle, Julio Rosenstock, John Gerich. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care*
http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=9&docId=GALE%7CA110470954&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA110470954&searchId=R3&userGroupName=leicester&inPS=true

99

Fineman MS, Cirincione BB, Maggs D, et al. GLP-1 based therapies: differential effects on fasting and postprandial glucose. *Diabetes, Obesity and Metabolism* 2012;**14**:675–88.

doi:10.1111/j.1463-1326.2012.01560.x

100

Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine* 2014;**31**:1293–300. doi:10.1111/dme.12561

101

Holman RR, Farmer AJ, Davies MJ, et al. Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. *New England Journal of Medicine* 2009;**361**:1736–47. doi:10.1056/NEJMoa0905479

102

Rosenstock J, Jelaska A, Frappin G, et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. *Diabetes Care* 2014;**37**:1815–23. doi:10.2337/dc13-3055

103

Bergenstal RM, Johnson M, Powers MA, et al. Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. *Diabetes Care* 2008;**31**:1305–10. doi:10.2337/dc07-2137

104

Owens DR, Luzio SD, Sert-Langeron C, et al. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. *Diabetes, Obesity and Metabolism* 2011;**13**:1020–7. doi:10.1111/j.1463-1326.2011.01459.x

105

Hannele Yki-Järvinen. Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? *Diabetes Care* 2013;**36**. doi:doi: 10.2337/dcS13-2026

106

Lankisch MR, Ferlinz KC, Leahy JL, et al. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. *Diabetes, Obesity and Metabolism* Published Online First: September 2008. doi:10.1111/j.1463-1326.2008.00967.x

107

Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. *Diabetologia* 2009;**52**:1990–2000. doi:10.1007/s00125-009-1468-7

108

Giugliano D, Maiorino MI, Bellastella G, et al. Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials. *Diabetes Care* 2011;**34**:510–7. doi:10.2337/dc10-1710

109

Raccah D, Huet D, Dib A, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine* Published Online First: 2 June 2017. doi:10.1111/dme.13390

110

Raccah D, Huet D, Dib A, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine* 2017;**34**:1193–204. doi:10.1111/dme.13390

111

Martha M. Funnell. Overcoming barriers to the initiation of insulin therapy. *Clinical Diabetes*
http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?sort=DA-SORT&docType=Article&tabID=T002&prodId=EAIM&searchId=R1&resultListType=RESULT_LIST&searchType=AdvancedSearchForm&contentSegment=¤tPosition=8&searchResultsType=SingleTab&inPS=true&userGroupName=leicester&docId=GALE%7CA159389875&contentSet=GALE%7CA159389875

112

McBain H, Begum S, Rahman S, et al. Barriers to and enablers of insulin self-titration in adults with Type 2 diabetes: a qualitative study. *Diabetic Medicine* 2017;**34**:253–61. doi:10.1111/dme.13196

113

Manju Chandran, Steven V. Edelman. Have insulin, will fly: diabetes management during air travel and time zone adjustment strategies. (Practical Pointers). *Clinical Diabetes* http://go.galegroup.com.ezproxy3.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=3&docId=GALE%7CA100730300&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA100730300&searchId=R2&userGroupName=leicester&inPS=true

114

Burnett JCD. Long- and Short-Haul Travel by Air: Issues for People With Diabetes on Insulin. *Journal of Travel Medicine* 2006;**13**:255–60. doi:10.1111/j.1708-8305.2006.00057.x

115

Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan - ClinicalKey. <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0149291808002737>

116

Hui E, Bravis V, Salih S, et al. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. *International Journal of Clinical Practice* 2010;**64**:1095–9. doi:10.1111/j.1742-1241.2010.02347.x

117

Ali S, Davies MJ, Brady EM, et al. Guidelines for managing diabetes in Ramadan. *Diabetic Medicine* 2016;**33**:1315–29. doi:10.1111/dme.13080

118

Bakiner O, Ertorer ME, Bozkirli E, et al. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. *Acta Diabetologica* 2009;**46**:63–5. doi:10.1007/s00592-008-0062-7

119

Gregory T. Mucha, Stacia Merkel, William Thomas, John P. Bantle. Fasting and insulin glargine in individuals with type 1 diabetes. *Diabetes Care*
http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=17&docId=GALE%7CA116666633&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA116666633&searchId=R8&userGroupName=leicester&inPS=true

120

Diabetes & Metabolism - Présentation - EM consulte.
<http://www.em-consulte.com/article/80031/alertePM#N1010C>

121

Mollema ED, Snoek FJ, Heine RJ, et al. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. *Diabetic Medicine* 2001;**18**:671–4. doi:10.1046/j.1464-5491.2001.00547.x

122

Jenkins K. II. Needle phobia: a psychological perspective. *British Journal of Anaesthesia* 2014;**113**:4–6. doi:10.1093/bja/aeu013

123

Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. *Diabetes Research and Clinical Practice* 1999;**46**:239–46. doi:10.1016/S0168-8227(99)00099-6

124

Mattoo V, Milicevic Z, Malone JK, et al. A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. *Diabetes Research and Clinical Practice* 2003;**59**:137–43. doi:10.1016/S0168-8227(02)00202-4

125

Akram J, De Verga V, Group the RS. Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan. *Diabetic Medicine* 1999;**16**:867–74. doi:10.1046/j.1464-5491.1999.00164.x

126

Hui E, Bravis V, Salih S, et al. Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. *International Journal of Clinical Practice* 2010;**64**:1095–9. doi:10.1111/j.1742-1241.2010.02347.x

127

Simmons JH, McFann KK, Brown AC, et al. Reliability of the Diabetes Fear of Injecting and Self-Testing Questionnaire in Pediatric Patients With Type 1 Diabetes. *Diabetes Care* 2007;**30**:987–8. doi:10.2337/dc06-1553

128

Crasto, W. *Handbook of Insulin Therapies*. Adis; 1st ed. 2016 edition 2016. <https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975>

129

Lambert K, Holt RIG. The use of insulin analogues in pregnancy. *Diabetes, Obesity and Metabolism* 2013;**15**:888–900. doi:10.1111/dom.12098

130

Hyperglycemia and Adverse Pregnancy Outcomes. *New England Journal of Medicine* 2008;**358**:1991–2002. doi:10.1056/NEJMoa0707943

131

Gurwitz JH. Glucocorticoids and the Risk for Initiation of Hypoglycemic Therapy. *Archives of Internal Medicine* 1994;**154**. doi:10.1001/archinte.1994.00420010131015

132

Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes - ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0002937815005931>

133

Simmons LR, Molyneaux L, Yue DK, et al. Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? *ISRN Endocrinology* 2012;**2012**:1–5. doi:10.5402/2012/910905

134

Riddle MC, Rosenstock J, Vlahjic A, et al. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. *Diabetes, Obesity and Metabolism* 2014;**16**:396–402. doi:10.1111/dom.12225

135

June James. End-of-life care: Anything but a pathway.
http://www.diabetesandprimarycare.co.uk/media/content/_master/3572/files/pdf/dpc15-6-292-7.pdf

136

Frisch A, Chandra P, Smiley D, et al. Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery. *Diabetes Care* 2010;**33**:1783–8. doi:10.2337/dc10-0304

137

Home P, Riddle M, Cefalu WT, et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? *Diabetes Care* 2014;**37**:1499–508. doi:10.2337/dc13-2743

138

Jackson MJ, Patvardhan C, Wallace F, et al. Perioperative management of diabetes in elective patients: a region-wide audit. *British Journal of Anaesthesia* 2016;**116**:501–6. doi:10.1093/bja/aev554

139

Rowles S, Kilvert A, Sinclair A. ABCD position statement on diabetes and end of life care. *Practical Diabetes International* 2011;**28**:26–7. doi:10.1002/pdi.1547

140

P. Schneiter. Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. *American Journal of Physiology - Endocrinology and Metabolism* 1998;**275**:E806–13. <http://ajpendo.physiology.org/content/275/5/E806>

141

Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy, Asthma & Clinical Immunology* 2013;**9**. doi:10.1186/1710-1492-9-30

142

Holman RR, Thorne KI, Farmer AJ, et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine* 2007;**357**:1716–30. doi:10.1056/NEJMoa075392

143

Kutz A, Struja T, Hausfater P, et al. The association of admission hyperglycaemia and adverse clinical outcome in medical emergencies: the multinational, prospective, observational TRIAGE study. *Diabetic Medicine* Published Online First: February 2017. doi:10.1111/dme.13325

144

Rowles S, Kilvert A, Sinclair A. ABCD position statement on diabetes and end of life care. *Practical Diabetes International* 2011;**28**:26–7. doi:10.1002/pdi.1547

145

Tapley M, Needham E. Improving end of life care for people with diabetes. *Practical Diabetes* 2012;**29**:306–307a. doi:10.1002/pdi.1711

146

Intensity of peri-operative glycaemic control and postoperative outcomes in patients with diabetes: a meta-analysis - ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822713001873>

147

F Game. *Annals of The Royal College of Surgeons of England*. 2012;**94**. doi:doi:10.1308/003588412X13171221591655

148

Hommel I, van Gorp PJ, Tack CJ, et al. Perioperative diabetes care: room for improving the person centredness. *Diabetic Medicine* 2015;**32**:561–8. doi:10.1111/dme.12600

149

Aldam P, Levy N, Hall GM. Perioperative management of diabetic patients: new controversies. *British Journal of Anaesthesia* 2014;**113**:906–9. doi:10.1093/bja/aeu259

150

Barker P, Creasey PE, Dhatariya K, et al. Peri-operative management of the surgical patient with diabetes 2015. *Anaesthesia* 2015;**70**:1427–40. doi:10.1111/anae.13233

151

Levy N, Penfold N, Mythen M. Perioperative management of diabetes and the emerging

role of anaesthetists as perioperative physicians. *British Journal of Anaesthesia* 2016;**116**:443–7. doi:10.1093/bja/aew049

152

Bajwa S, Baruah M, Kalra S, et al. Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive care. *Journal of Anaesthesiology Clinical Pharmacology* 2015;**31**. doi:10.4103/0970-9185.155141

153

Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. *Diabetes/Metabolism Research and Reviews* 2014;**30**:96–102. doi:10.1002/dmrr.2486

154

Gururaj Setty S, Crasto W, Jarvis J, et al. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal* 2016;**92**:152–64. doi:10.1136/postgradmedj-2015-133716

155

Crasto, W. *Handbook of Insulin Therapies*. Adis; 1st ed. 2016 edition 2016. <https://ebookcentral.proquest.com/lib/leicester/detail.action?docID=4676975>

156

Bergenstal RM, Rosenstock J, Arakaki RF, et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. *Diabetes Care* 2012;**35**:2140–7. doi:10.2337/dc12-0060

157

Rosenstock J, Bergenstal RM, Blevins TC, et al. Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. *Diabetes Care* 2013;**36**:522–8. doi:10.2337/dc12-0067

158

Riddle MC, Bolli GB, Ziemien M, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). *Diabetes Care* 2014;**37**:2755–62. doi:10.2337/dc14-0991

159

Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). *Diabetes Care* 2015;**38**:2217–25. doi:10.2337/dc15-0249

160

New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-Analysis of Phase 3a EDITION Clinical Trials in People with T2DM - ClinicalKey.
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1499267114003086>

161

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes - ClinicalKey.
<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858714701743>

162

Buse JB, Vilsbøll T, Thurman J, et al. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). *Diabetes Care* 2014;**37**:2926–33. doi:10.2337/dc14-0785

163

EASD Virtual Meeting.
<http://www.easdvirtualmeeting.org/resources/systematic-review-and-meta-analysis-of-the->

efficacy-and-safety-of-sglt2-inhibitors-in-patients-with-type-2-diabetes-mellitus

164

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial - ClinicalKey.
<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673610606320>

165

Shosuke Satake, Mary Courtney Moore, Kayano Igawa, Margaret Converse, Benjamin Farmer, Doss W. Neal. Direct and indirect effects of insulin on glucose uptake and storage by the liver. (Original Articles). Diabetes
http://go.galegroup.com.ezproxy4.lib.le.ac.uk/ps/retrieve.do?tabID=T002&resultListType=RESULT_LIST&searchResultsType=SingleTab&searchType=AdvancedSearchForm¤tPosition=2&docId=GALE%7CA87347789&docType=Article&sort=Relevance&contentSegment=&prodId=EAIM&contentSet=GALE%7CA87347789&searchId=R8&userGroupName=leicester&inPS=true

166

Khedkar A, Iyer H, Anand A, et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes, Obesity and Metabolism 2010;**12**:659-64. doi:10.1111/j.1463-1326.2010.01213.x

167

Luzio SD, Dunseath G, Lockett A, et al. The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes, Obesity and Metabolism 2010;**12**:82-7. doi:10.1111/j.1463-1326.2009.01146.x

168

W. Blair Geho. A Single-blind, Placebo-controlled, Dose-ranging Trial of Oral Hepatic-directed Vesicle Insulin Add-on to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus. Journal of Diabetes Science and Technology 2014;**8**. doi:doi:10.1177/1932296814524871

169

Morçöl T, Nagappan P, Nerenbaum L, et al. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. *International Journal of Pharmaceutics* 2004; **277**:91–7. doi:10.1016/j.ijpharm.2003.07.015

170

Pozzilli P, Manfrini S, Costanza F, et al. Biokinetics of buccal spray insulin in patients with type 1 diabetes. *Metabolism* 2005; **54**:930–4. doi:10.1016/j.metabol.2005.02.008

171

Guevara-Aguirre J, Guevara M, Saavedra J, et al. Beneficial Effects of Addition of Oral Spray Insulin (Oralin) on Insulin Secretion and Metabolic Control in Subjects with Type 2 Diabetes Mellitus Suboptimally Controlled on Oral Hypoglycemic Agents. *Diabetes Technology & Therapeutics* 2004; **6**:1–8. doi:10.1089/152091504322783341

172

Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. *The British Journal of Diabetes & Vascular Disease* 2010; **10**:90–7. doi:10.1177/1474651409355454

173

Raccah D, Huet D, Dib A, et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine* 2017; **34**:1193–204. doi:10.1111/dme.13390

174

Lea, Mary R. *Writing At University*. 3rd ed. McGraw-Hill Education 2008. <http://ebookcentral.proquest.com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=345134>

175

Bailey S. *Academic writing: a handbook for international students*. 3rd ed. London: : Routledge 2011. <http://ezproxy.lib.le.ac.uk/login?url=http://www.mylibrary.com?id=310467>